Stephen Oesterle
Venture Partner @ Cathay Capital
Minneapolis, United States
Stephen Oesterle is a Series A investor at Cathay Capital in Minneapolis focused on Medical and Health Care. Stephen Oesterle
- Total investments:
- 3
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Stephen Oesterle invests in
Stages Stephen Oesterle invests in
Countries Stephen Oesterle invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 2 (67%)
- Health Care 2 (67%)
- Biotechnology 2 (67%)
- Therapeutics 1 (33%)
- Health Diagnostics 1 (33%)
Stage
- Series A 1 (33%)
- Series C 1 (33%)
- Series D 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Semma Therapeutics
|
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to SemmaTherapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes. | $44M / Series A / Mar 24, 2015 | |
PowerVision
|
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again. | $20M / Series D / Jan 29, 2014 | |
|
PowerVision
|
PowerVision is a private company focused on developing a novel accommodating intraocular lens, which is designed to restore True AccommodationTM. Their innovative FluidVisionTM accommodating intraocular lens (IOL) is poised to help individuals affected by presbyopia and/or cataracts regain the ability to dynamically adjust focus for clearvision at all distances.Fifty years ago, vision correction surgery was changed forever by the invention of the intraocular lens, which is used to treat a cataract – a clouding and hardening of the dime-sized, normally clear, crystalline lens inside your eye which can rob you of your vision in your 60’s, 70’s and 80’s.PowerVision set out to dramatically improve vision correction surgery again. They began the development of their FluidVision IOL, which mimics the way a healthy eye works and can restore clear vision at all distances, near, far, and everywhere in between. It uses a tiny amount of fluid inside the lens and natural eye muscles to change shape and adjust focus just the way your healthy eye does.For the more than 20 million people with cataracts in the U.S. and, ultimately, the more than 90 million with Presbyopia – the loss of ability to focus up close that affects people in their 40’s and 50’s – the FluidVision lens can potentially give them freedom from ever needing glasses, contacts or any vision correction procedure again. | $24M / Series C / Jul 15, 2011 |
Co-Investors
About Cathay Capital
Cathay Capital is a leading international private equity firm active in cross-border investment. It supports the international expansion of middle-market companies in North America, China and Europe. Its team of 60 professionals based in New York, Shanghai, Beijing, Paris, Munich, and Silicon Valley leverages Cathay's business model andplatform to create value for companies. With more than $1.5 billion in assets under management, Cathay Capital has completed buyouts and growth capital investments in 59 platform companies across three continents.
Cathay Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Matthieu van der Elst
Chief Impact Officer
|
|||
Mingpo Cai
Founder & President
|
|||
Stephan Torra
Partner
|
|||
|
Stephen Oesterle
Venture Partner
|
|||
Zhao Jing
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Stephen Oesterle invest in?
Stephen Oesterle invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Stephen Oesterle?
Public channels for Stephen Oesterle include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Stephen Oesterle last invest?
The most recent investment recorded for Stephen Oesterle closed in Mar 2015. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
